Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients

CR1447 (4-hydroxytestosterone, 4-OHT) binds to the androgen receptor and has antiproliferative activity in both ER-positive and ER-negative/AR-positive breast cancer cells in preclinical studies. The objective of this first-in man trial was to evaluate the safety and to determine the dose of CR1447,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zweifel, Martin, Thürlimann, Beat, Riniker, Salome, Weder, Patrik, von Moos, Roger, Pagani, Olivia, Bigler, Martin, Rothgiesser, Karin M, Pilop, Christiane, Hawle, Hanne, Brauchli, Peter, Tapia, Coya, Schoenfeld, Wolfgang, Sessa, Cristiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606553/
https://www.ncbi.nlm.nih.gov/pubmed/28814476
http://dx.doi.org/10.1530/EC-17-0174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5606553/
https://www.ncbi.nlm.nih.gov/pubmed/28814476
http://dx.doi.org/10.1530/EC-17-0174

Ejemplares similares